Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance - Takeaways - MDSpire

Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance

  • By

  • Maliheh Hasannia

  • Mahdi Abounoori

  • Fatemeh Mahmoudian

  • Maryam Shirzad

  • Abbas Rahdar

  • Selamu Duguna

  • Sadanand Pandey

  • June 17, 2026

  • 0 min

Share

  • 1

    Chemoresistance significantly limits the efficacy of conventional chemotherapy and contributes to tumor recurrence and metastasis.

  • 2

    The tumor microenvironment (TME) creates barriers to drug penetration, including hypoxia, acidic pH, and immune suppression.

  • 3

    Intelligent nanomedicine offers a transformative approach by enhancing drug delivery and remodeling the TME to overcome chemoresistance.

  • 4

    Stimuli-responsive nanocarriers can improve drug accumulation in tumors and actively modify the TME through various therapeutic mechanisms.

  • 5

    TME-targeted intelligent nanomedicine represents a paradigm shift in cancer treatment, aiming to improve efficacy while reducing systemic toxicity.

Original Source(s)

Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance

  • by Maliheh Hasannia, Mahdi Abounoori, Fatemeh Mahmoudian, Maryam Shirzad, Abbas Rahdar, Selamu Duguna, Sadanand Pandey

  • June 17, 2026

Related Content

Fusion protein-mediated costimulation in engineered T cells: from intrinsic signaling to tumor microenvironment rewiring

Spontaneous intracerebral hemorrhage associated with lenvatinib in advanced hepatocellular carcinoma without conventional risk factors: a case report literature review

The aMAP score improves discrimination of prognostic models in hepatocellular carcinoma after radiofrequency ablation